thalidomide has been researched along with Cancer of Stomach in 9 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study we subjected the gastric cancer cell line AGS to chronic exposure of 5-fluorouracil, cisplatin or paclitaxel, thus selecting cell subpopulations showing resistance to the different drugs." | 1.62 | Enhanced Vasculogenic Capacity Induced by 5-Fluorouracil Chemoresistance in a Gastric Cancer Cell Line. ( Andreucci, E; Barbato, G; Biagioni, A; Cianchi, F; Coratti, F; Giovannelli, L; Magnelli, L; Papucci, L; Peri, S; Schiavone, N; Staderini, F; Versienti, G, 2021) |
| "Our results demonstrated that thalidomide combined with capecitabine was mildly effective and safe for treating elderly patients with advanced GC." | 1.48 | Thalidomide combined with chemotherapy in treating elderly patients with advanced gastric cancer. ( Chu, Y; Li, Y; Song, R; Xu, F, 2018) |
| "Thalidomide treatment was associated with significant down-regulation of nuclear NF-κB expression levels in residual neoplastic cells and microenvironments of responsive tumors, but not in t(11;18)(q21;q21)-positive, thalidomide-refractory tumors." | 1.37 | t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement. ( Chen, LT; Cheng, AL; Hsu, CH; Kuo, SH; Lin, CW; Tzeng, YS; Wu, MS; Yeh, KH, 2011) |
| "Thalidomide was prescribed for its antiangiogenic properties." | 1.35 | The use of thalidomide in the management of bleeding from a gastric cancer. ( Lambert, K; Ward, J, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Peri, S | 1 |
| Biagioni, A | 1 |
| Versienti, G | 1 |
| Andreucci, E | 1 |
| Staderini, F | 1 |
| Barbato, G | 1 |
| Giovannelli, L | 1 |
| Coratti, F | 1 |
| Schiavone, N | 1 |
| Cianchi, F | 1 |
| Papucci, L | 1 |
| Magnelli, L | 1 |
| Li, Y | 1 |
| Chu, Y | 1 |
| Song, R | 1 |
| Xu, F | 1 |
| Carras, S | 1 |
| Regny, C | 1 |
| Peoc'h, M | 1 |
| Gervasoni, J | 1 |
| Gressin, R | 1 |
| Cahn, JY | 1 |
| Molina, L | 1 |
| Lambert, K | 1 |
| Ward, J | 1 |
| Troch, M | 1 |
| Zielinski, C | 1 |
| Raderer, M | 1 |
| Ong, SJ | 1 |
| Teo, M | 1 |
| Lim, KH | 1 |
| Choo, SP | 1 |
| Toh, HC | 1 |
| Kuo, SH | 1 |
| Cheng, AL | 1 |
| Lin, CW | 1 |
| Hsu, CH | 1 |
| Wu, MS | 1 |
| Yeh, KH | 1 |
| Tzeng, YS | 1 |
| Chen, LT | 1 |
| Gaur, S | 1 |
| Oo, TH | 1 |
| Aish, LS | 1 |
| Mansoor, S | 1 |
| Roe, FJ | 1 |
| Walters, MA | 1 |
9 other studies available for thalidomide and Cancer of Stomach
| Article | Year |
|---|---|
Enhanced Vasculogenic Capacity Induced by 5-Fluorouracil Chemoresistance in a Gastric Cancer Cell Line.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Endothelial Cells; Fl | 2021 |
Thalidomide combined with chemotherapy in treating elderly patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2018 |
Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Le | 2015 |
The use of thalidomide in the management of bleeding from a gastric cancer.
Topics: Aged; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Stomach Neoplasms; Thali | 2009 |
Absence of efficacy of thalidomide monotherapy in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
Topics: Adult; Aged; Conjunctival Neoplasms; Duodenal Neoplasms; Female; Humans; Lymphoma, B-Cell, Marginal | 2009 |
Rapamycin and thalidomide treatment of a patient with refractory metastatic gastroesophageal adenocarcinoma: a case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophag | 2010 |
t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement.
Topics: Aged; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 18; Disease-Free Survival; Female; Human | 2011 |
Gastric relapse of solitary bone plasmacytoma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combin | 2005 |
Sensitivity of newborn mice to carcinogenic agents.
Topics: Adenocarcinoma; Adenoma; Animals; Animals, Newborn; Benz(a)Anthracenes; Carcinogens; Carcinoma, Hepa | 1968 |